Jonathan Tobin speaks to Vox Markets about Artios and its new ATR inhibitor programme

Vox Markets Daily

7th November 2019

Jonathan Tobin, Investment Director, speaks to Vox Markets about our portfolio companies Artios Pharma which has announced the expansion of its DNA Damage Response pipeline with a new asset.

Stay Updated

Add your email below to stay updated with useful and informative content from Arix and our portfolio companies